Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · Real-Time Price · USD
29.83
-0.26 (-0.86%)
May 18, 2026, 4:00 PM EDT - Market closed
HRMY Stock Forecast
Stock Price Forecast
The 11 analysts that cover HRMY stock have a consensus rating of "Buy" and an average price target of $44.36, which forecasts a 48.71% increase in the stock price over the next year. The lowest target is $28 and the highest is $85.
Price Target: $44.36 (+48.71%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for HRMY stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 5 | 3 |
| Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 2 | 2 | 2 | 3 |
| Sell | 0 | 0 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 10 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Hold Maintains $25 → $29 | Hold | Maintains | $25 → $29 | -2.78% | May 8, 2026 |
| UBS | UBS | Hold Maintains $46 → $36 | Hold | Maintains | $46 → $36 | +20.68% | Feb 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +84.38% | Feb 25, 2026 |
| B of A Securities | B of A Securities | Sell Maintains $32 → $28 | Sell | Maintains | $32 → $28 | -6.13% | Feb 25, 2026 |
| Needham | Needham | Strong Buy Maintains $46 → $44 | Strong Buy | Maintains | $46 → $44 | +47.50% | Feb 25, 2026 |
Financial Forecast
Revenue This Year
1.04B
from 868.45M
Increased by 19.87%
Revenue Next Year
1.18B
from 1.04B
Increased by 13.16%
EPS This Year
3.57
from 2.71
Increased by 31.70%
EPS Next Year
4.32
from 3.57
Increased by 21.16%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.1B | 1.3B | ||||||
| Avg | 1.0B | 1.2B | ||||||
| Low | 964.0M | 918.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 26.9% | 27.8% | ||||||
| Avg | 19.9% | 13.2% | ||||||
| Low | 11.0% | -11.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 4.62 | 6.66 | |||
| Avg | 3.57 | 4.32 | |||
| Low | 2.47 | 3.04 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 70.5% | 86.5% | |||
| Avg | 31.7% | 21.2% | |||
| Low | -8.9% | -14.9% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.